TECH
Bio-Techne Corporation NASDAQ Listed Feb 9, 1989$57.94
+5.35%
vs $55.00
Mkt Cap $9.1B
52w Low $43.20
50.9% of range
52w High $72.16
50d MA $52.49
200d MA $57.49
P/E (TTM)
126.0x
EV/EBITDA
43.5x
P/B
4.8x
Debt/Equity
0.2x
ROE
3.8%
P/FCF
36.1x
RSI (14)
66.80
ATR (14)
$1.92
Beta
1.49
50d MA
$52.49
200d MA
$57.49
Avg Volume
3.1M
Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research and clinical diagnostic markets worldwide. The company operates through two segments, Protein Sciences, and Diagnostics and Genomics. The Protein Sciences segment develops and manufactures biological reagents used in various aspects of life science research, diagnostics, and cell and gene therapy, such as cytokines and growth factors, antibodies, small molecules, tissue culture sera, and cell selection technologies. This segment also offers proteomic analytical tools for automated western blot and multiplexed ELISA workflow consists of manual and automated protein analysis instruments and immunoassays for use in quantifying proteins in various biological fluids. The Diagnostics and Genomics segment develops and manufactures diagnostic products, including controls, calibrators, and diagnostic assays for regulated diagnostics market, exosome-based molecular diagnostic assays, advanced tissue-based in-situ hybridization assays for spatial genomic and tissue biopsy analysis, and genetic and oncology kits for research and clinical applications; and sells products for genetic carrier screening, oncology diagnostics, molecular controls, and research, as well as instruments and process control products for hematology, blood chemistry and gases, and coagulation controls and reagents used in various diagnostic applications. It offers its products under R&D Systems, Tocris Biosciences, Novus Biologicals, ProteinSimple, Advanced Cell Diagnostics, Exosome Diagnostics, and Asuragen brands. The company was formerly known as Techne Corporation and changed its name to Bio-Techne Corporation in November 2014. Bio-Techne Corporation was founded in 1976 and is headquartered in Minneapolis, Minnesota.
614 McKinley Place N.E. · Minneapolis, MN 55413 · US
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| May 6, 2026 | TNS | 0.55 | 0.53 | -3.6% | 47.41 | -0.4% | +7.4% | -5.0% | -1.9% | +0.0% | -5.3% | — |
| Feb 4, 2026 | TNS | 0.43 | 0.46 | +7.0% | 68.67 | -0.9% | -4.1% | +1.4% | -1.9% | -1.0% | -2.1% | — |
| Nov 5, 2025 | TNS | 0.42 | 0.42 | -0.3% | 59.94 | +0.8% | -2.9% | -1.3% | +0.1% | +3.0% | +3.8% | — |
| Aug 6, 2025 | TNS | 0.50 | 0.53 | +6.1% | 49.87 | +1.3% | +0.6% | +0.5% | -0.5% | +5.3% | +3.6% | — |
| May 7, 2025 | TNS | 0.51 | 0.56 | +10.2% | 48.75 | -0.3% | +2.1% | +0.3% | +7.9% | -4.2% | -7.3% | — |
| Feb 5, 2025 | TNS | 0.39 | 0.42 | +8.8% | 75.25 | +2.4% | -0.3% | -2.9% | -4.0% | -2.3% | -1.3% | — |
| Oct 30, 2024 | TNS | 0.38 | 0.42 | +10.5% | 76.02 | -0.2% | -3.0% | +2.1% | +0.8% | +2.3% | -2.3% | — |
| Aug 7, 2024 | TNS | 0.49 | 0.49 | -1.0% | 70.96 | +1.3% | +3.4% | -2.2% | +0.0% | +2.3% | -1.0% | — |
| May 1, 2024 | TNS | 0.45 | 0.48 | +6.0% | 73.46 | +1.3% | +2.9% | +2.2% | -1.6% | +1.8% | -0.5% | — |
| Feb 1, 2024 | TNS | 0.41 | 0.40 | -3.0% | 68.54 | -2.7% | -3.7% | +1.2% | +0.9% | -1.5% | +2.4% | — |
| Oct 31, 2023 | TNS | 0.44 | 0.41 | -6.8% | 54.63 | +0.5% | -3.3% | +4.9% | +6.0% | -0.1% | +1.6% | — |
| Aug 8, 2023 | TNS | 0.55 | 0.55 | +0.0% | 84.30 | -0.1% | -1.5% | +0.0% | +1.7% | +0.5% | -0.2% | — |
| May 3, 2023 | BMO | 0.53 | 0.53 | +0.0% | 85.98 | -0.2% | -2.3% | -1.1% | -1.0% | -1.4% | +0.1% | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Jun 11 | Piper Sandler | Initiates | Neutral | $65 | $52.50 | $52.50 | +0.0% | +2.9% | -0.0% | +4.0% | -0.2% | -1.8% |
| May 15 | RBC Capital Mkts | Reiterates | Outperform | $62 | $44.74 | $44.84 | +0.2% | -3.2% | +2.6% | +2.3% | +2.7% | +1.4% |
| Apr 6 | Evercore ISI | Maintains | In Line → In Line | — | $53.13 | $53.13 | +0.0% | +1.3% | +0.1% | +2.6% | +0.7% | -0.1% |
| Feb 6 | Wells Fargo | Maintains | Overweight → Overweight | — | $65.86 | $66.76 | +1.4% | +1.4% | -1.9% | -1.0% | -2.1% | -6.2% |
| Feb 5 | UBS | Maintains | Buy → Buy | — | $68.67 | $68.04 | -0.9% | -4.1% | +1.4% | -1.9% | -1.0% | -2.1% |
| Feb 5 | TD Cowen | Maintains | Buy → Buy | — | $68.67 | $68.04 | -0.9% | -4.1% | +1.4% | -1.9% | -1.0% | -2.1% |
| Feb 5 | Evercore ISI | Maintains | In Line → In Line | — | $68.67 | $68.04 | -0.9% | -4.1% | +1.4% | -1.9% | -1.0% | -2.1% |
| Feb 5 | Citigroup | Maintains | Buy → Buy | — | $68.67 | $68.04 | -0.9% | -4.1% | +1.4% | -1.9% | -1.0% | -2.1% |
| Feb 5 | Stifel | Maintains | Hold → Hold | — | $68.67 | $68.04 | -0.9% | -4.1% | +1.4% | -1.9% | -1.0% | -2.1% |
| Jan 5 | Evercore ISI | Downgrade | Outperform → In Line | — | $59.65 | $59.05 | -1.0% | +5.7% | +3.6% | -0.4% | -0.7% | +1.7% |
| Nov 20 | Argus | Maintains | Buy → Buy | — | $57.81 | $59.10 | +2.2% | +1.6% | +4.8% | +3.2% | +3.7% | -1.9% |
| Nov 6 | UBS | Maintains | Buy → Buy | — | $59.94 | $60.43 | +0.8% | -2.9% | -1.3% | +0.1% | +3.0% | +3.8% |
| Nov 6 | Wells Fargo | Maintains | Overweight → Overweight | — | $59.94 | $60.43 | +0.8% | -2.9% | -1.3% | +0.1% | +3.0% | +3.8% |
| Oct 14 | TD Cowen | Maintains | Buy → Buy | — | $59.65 | $58.73 | -1.5% | -0.6% | +0.5% | +3.4% | +0.4% | +1.1% |
| Oct 7 | Evercore ISI | Maintains | Outperform → Outperform | — | $61.92 | $62.10 | +0.3% | -4.4% | +2.3% | -1.1% | -2.1% | +1.7% |
| Sep 3 | RBC Capital | Upgrade | Sector Perform → Outperform | — | $53.42 | $53.60 | +0.3% | -0.1% | -0.8% | +2.8% | -0.6% | +0.2% |
| Aug 21 | Citigroup | Upgrade | Neutral → Buy | — | $54.33 | $54.66 | +0.6% | -0.6% | +5.7% | -0.7% | +0.1% | -1.0% |
| Aug 7 | RBC Capital | Maintains | Sector Perform → Sector Perform | — | $49.87 | $50.51 | +1.3% | +0.6% | +0.5% | -0.5% | +5.3% | +3.6% |
| Jul 11 | Scotiabank | Maintains | Sector Outperform → Sector Outperform | — | $54.41 | $53.68 | -1.3% | -0.5% | -2.8% | -2.3% | +0.7% | +2.9% |
| Jun 5 | Benchmark | Maintains | Buy → Buy | — | $49.85 | $49.80 | -0.1% | -3.1% | +0.8% | +2.4% | +3.0% | +0.3% |
| May 9 | UBS | Maintains | Buy → Buy | — | $49.78 | $50.00 | +0.4% | +0.3% | +7.9% | -4.2% | -7.3% | +0.8% |
| May 8 | RBC Capital | Maintains | Sector Perform → Sector Perform | — | $48.75 | $48.59 | -0.3% | +2.1% | +0.3% | +7.9% | -4.2% | -7.3% |
| May 8 | Benchmark | Maintains | Buy → Buy | — | $48.75 | $48.59 | -0.3% | +2.1% | +0.3% | +7.9% | -4.2% | -7.3% |
| May 8 | Stifel | Maintains | Hold → Hold | — | $48.75 | $48.59 | -0.3% | +2.1% | +0.3% | +7.9% | -4.2% | -7.3% |
| Apr 9 | KeyBanc Capital Markets | Downgrade | Overweight → Sector Weight | — | $48.81 | $46.53 | -4.7% | +10.8% | -8.9% | +3.0% | +3.6% | -2.8% |
| Apr 8 | KeyBanc Capital Markets | Downgrade | Overweight → Sector Weight | — | $52.31 | $53.26 | +1.8% | -6.7% | +10.8% | -8.9% | +3.0% | +3.6% |
| Mar 4 | Citigroup | Maintains | Neutral → Neutral | — | $61.19 | $60.70 | -0.8% | -1.7% | +3.5% | +1.9% | +1.5% | -2.3% |
| Feb 19 | Baird | Downgrade | Outperform → Neutral | — | $65.29 | $63.52 | -2.7% | +0.8% | -0.5% | -0.9% | +1.0% | -2.0% |
| Feb 6 | KeyBanc Capital Markets | Maintains | Overweight → Overweight | — | $75.25 | $77.03 | +2.4% | -0.3% | -2.9% | -4.0% | -2.3% | -1.3% |
| Feb 6 | RBC Capital | Maintains | Sector Perform → Sector Perform | — | $75.25 | $77.03 | +2.4% | -0.3% | -2.9% | -4.0% | -2.3% | -1.3% |
| Feb 6 | Baird | Maintains | Outperform → Outperform | — | $75.25 | $77.03 | +2.4% | -0.3% | -2.9% | -4.0% | -2.3% | -1.3% |
| Feb 6 | Scotiabank | Maintains | Sector Outperform → Sector Outperform | — | $75.25 | $77.03 | +2.4% | -0.3% | -2.9% | -4.0% | -2.3% | -1.3% |
| Oct 31 | Baird | Maintains | Outperform → Outperform | — | $76.02 | $75.89 | -0.2% | -3.0% | +2.1% | +0.8% | +2.3% | -2.3% |
| Oct 31 | Scotiabank | Maintains | Sector Outperform → Sector Outperform | — | $76.02 | $75.89 | -0.2% | -3.0% | +2.1% | +0.8% | +2.3% | -2.3% |
| Aug 13 | Benchmark | Maintains | Buy → Buy | — | $71.78 | $71.65 | -0.2% | +2.3% | -1.0% | +3.0% | -0.5% | +0.6% |
| Aug 8 | RBC Capital | Maintains | Sector Perform → Sector Perform | — | $70.96 | $71.90 | +1.3% | +3.4% | -2.2% | +0.0% | +2.3% | -1.0% |
| Aug 8 | Baird | Maintains | Outperform → Outperform | — | $70.96 | $71.90 | +1.3% | +3.4% | -2.2% | +0.0% | +2.3% | -1.0% |
| May 22 | Citigroup | Downgrade | Buy → Neutral | — | $82.68 | $80.97 | -2.1% | +0.4% | -3.1% | +0.5% | -1.7% | -1.0% |
| May 2 | Baird | Maintains | Outperform → Outperform | — | $73.46 | $74.45 | +1.3% | +2.9% | +2.2% | -1.6% | +1.8% | -0.5% |
| May 2 | Benchmark | Maintains | Buy → Buy | — | $73.46 | $74.45 | +1.3% | +2.9% | +2.2% | -1.6% | +1.8% | -0.5% |
| Apr 18 | Deutsche Bank | Maintains | Buy → Buy | — | $62.73 | $61.61 | -1.8% | -0.8% | -0.1% | +1.1% | +1.4% | -0.3% |
| Feb 2 | Stifel | Downgrade | Buy → Hold | — | $68.54 | $66.68 | -2.7% | -3.7% | +1.2% | +0.9% | -1.5% | +2.4% |
| Feb 2 | Stephens & Co. | Maintains | Overweight → Overweight | — | $68.54 | $66.68 | -2.7% | -3.7% | +1.2% | +0.9% | -1.5% | +2.4% |
| Feb 2 | RBC Capital | Maintains | Sector Perform → Sector Perform | — | $68.54 | $66.68 | -2.7% | -3.7% | +1.2% | +0.9% | -1.5% | +2.4% |
| Nov 2 | Stifel | Maintains | Buy → Buy | — | $52.83 | $53.77 | +1.8% | +4.9% | +6.0% | -0.1% | +1.6% | -1.6% |
| Nov 1 | RBC Capital | Maintains | Sector Perform → Sector Perform | — | $54.63 | $54.93 | +0.5% | -3.3% | +4.9% | +6.0% | -0.1% | +1.6% |
| Nov 1 | KeyBanc Capital Markets | Maintains | Overweight → Overweight | — | $54.63 | $54.93 | +0.5% | -3.3% | +4.9% | +6.0% | -0.1% | +1.6% |
| Nov 1 | Citigroup | Maintains | Buy → Buy | — | $54.63 | $54.93 | +0.5% | -3.3% | +4.9% | +6.0% | -0.1% | +1.6% |
| Sep 12 | RBC Capital | Maintains | Sector Perform → Sector Perform | — | $71.63 | $71.21 | -0.6% | +0.5% | +0.7% | +2.1% | -0.5% | -3.4% |
| Aug 18 | Benchmark | Maintains | Buy → Buy | — | $80.24 | $79.59 | -0.8% | -2.5% | +0.6% | -0.6% | +0.6% | +0.1% |
| Date | Insider | Title | Type | Shares | Price | Value | Owned After | D1% | D5% |
|---|---|---|---|---|---|---|---|---|---|
| May 8, 2026 | Herr Amy E.Dir | — | Sell | 6,636 | $48.28 | $320K | 200 | -5.34% | +2.34% |
8-K · 2.02
!! High
Bio-Techne Corporation -- 8-K 2.02: Earnings Results
Bio-Techne Corporation reported Q2 2026 earnings results for the quarter and nine months ended March 31, 2026, disclosing operational performance and financial condition metrics to shareholders.
May 6
8-K · 5.02
!!! Very High
Bio-Techne Corp. -- 8-K 5.02: Executive Change
Bio-Techne's Diagnostics and Spatial Biology segment President Matt McManus is departing March 1, 2026, though he'll remain temporarily to ensure transition continuity.
Feb 11
8-K · 8.01
!! High
Bio-Techne Corp. -- 8-K 8.01: Material Event / Announcement
Bio-Techne Corporation announced a cash dividend, signaling confidence in its financial position and returning capital to shareholders.
Feb 4
Institutional (13F) — Top 20
All ↗
| # | Manager | Shares | Value | Chg | Period |
|---|---|---|---|---|---|
| 1 | Morgan Stanley | 16,690,828 | $982M | Added | Dec 2025 |
| 2 | Vanguard Capital Management Llc | 10,179,709 | $532M | New | Mar 2026 |
| 3 | Fmr Llc | 7,899,928 | $413M | Added | Mar 2026 |
| 4 | Vanguard Portfolio Management Llc | 6,480,337 | $339M | New | Mar 2026 |
| 5 | Maverick Capital Ltd | 4,739,721 | $248M | Added | Mar 2026 |
| 6 | Invesco Ltd. | 4,588,706 | $240M | Added | Mar 2026 |
| 7 | Durable Capital Partners Lp | 4,456,017 | $233M | Added | Mar 2026 |
| 8 | Ruane, Cunniff & Goldfarb L.p. | 3,392,001 | $177M | Added | Mar 2026 |
| 9 | Neuberger Berman Group Llc | 3,340,837 | $175M | Added | Mar 2026 |
| 10 | Select Equity Group, L.p. | 2,837,142 | $167M | Added | Dec 2025 |
| 11 | Capital Research Global Investors | 3,188,210 | $167M | Added | Mar 2026 |
| 12 | Ubs Group Ag | 3,054,343 | $160M | Added | Mar 2026 |
| 13 | Mairs & Power Inc | 2,750,282 | $144M | Reduced | Mar 2026 |
| 14 | William Blair Investment Management, Llc | 2,462,487 | $129M | Added | Mar 2026 |
| 15 | Bank Of New York Mellon Corp | 1,759,119 | $92M | Reduced | Mar 2026 |
| 16 | Champlain Investment Partners, Llc | 1,454,171 | $76M | Added | Mar 2026 |
| 17 | Madison Asset Management, Llc | 1,181,308 | $69M | Added | Dec 2025 |
| 18 | Northern Trust Corp | 1,324,258 | $69M | Reduced | Mar 2026 |
| 19 | First Trust Advisors Lp | 1,281,792 | $67M | Added | Mar 2026 |
| 20 | Geneva Capital Management Llc | 1,243,043 | $65M | Added | Mar 2026 |
Mutual Funds / ETFs (N-PORT) — Top 20
All ↗
| # | Fund | Shares | Value | Period |
|---|---|---|---|---|
| 1 | VANGUARD HEALTH CARE FUND | 2,720,122 | $174M | Jan 2026 |
| 2 | Invesco S&P 500 Equal Weight ETF | 2,620,354 | $168M | Jan 2026 |
| 3 | Fidelity 500 Index Fund | 1,982,900 | $117M | Feb 2026 |
| 4 | iShares Core S&P 500 ETF | 2,007,240 | $105M | Mar 2026 |
| 5 | Mairs & Power Growth Fund | 1,411,001 | $74M | Mar 2026 |
| 6 | Sequoia Fund Inc | 1,303,294 | $68M | Mar 2026 |
| 7 | Select Medical Technology and Devices Portfolio | 1,080,000 | $64M | Feb 2026 |
| 8 | iShares Biotechnology ETF | 1,151,950 | $60M | Mar 2026 |
| 9 | Strategic Advisers U.S. Total Stock Fund | 738,432 | $44M | Feb 2026 |
| 10 | Heritage Fund | 615,031 | $39M | Jan 2026 |
| 11 | MFS New Discovery Fund | 644,777 | $38M | Feb 2026 |
| 12 | Madison Mid Cap Fund | 593,396 | $38M | Jan 2026 |
| 13 | ClearBridge Mid Cap Fund | 501,000 | $32M | Jan 2026 |
| 14 | iShares Russell Mid-Cap ETF | 593,352 | $31M | Mar 2026 |
| 15 | AB Discovery Value Fund | 513,776 | $30M | Feb 2026 |
| 16 | Strategic Advisers Fidelity U.S. Total Stock Fund | 458,424 | $27M | Feb 2026 |
| 17 | Schwab U.S. Mid-Cap ETF | 420,540 | $25M | Feb 2026 |
| 18 | U.S. SMALL CAP PORTFOLIO | 366,996 | $24M | Jan 2026 |
| 19 | Schwab S&P 500 Index Fund | 349,979 | $22M | Jan 2026 |
| 20 | THE HARTFORD MIDCAP FUND | 320,193 | $21M | Jan 2026 |
Valuation
Market Cap
$9.07B
Enterprise Value
$9.44B
P/E (TTM)
125.96x
Forward P/E
29.24x
PEG Ratio
-1.97x
P/B
4.76x
P/S
7.59x
P/FCF
36.07x
EV/EBITDA
43.52x
Shares Out
159.7M
Financials (TTM)
Revenue
$1.22B
Net Income
$73.4M
EBITDA
$216.9M
Free Cash Flow
$256.6M
Op Cash Flow
$287.6M
EPS Basic
$0.47
EPS Diluted
$0.46
EPS Forward
$1.98
Gross Margin
64.8%
Op Margin
8.4%
Net Margin
6.0%
Balance Sheet
Total Assets
$2.56B
Total Liab.
$639.1M
Total Equity
$1.92B
Cash
$162.2M
LT Debt
$346.0M
Book Value/Sh
$12.18
Debt/Equity
0.23x
Current Ratio
3.46
Quick Ratio
2.38
Returns & Growth
ROE
3.8%
ROA
3.0%
ROIC
3.2%
Rev Growth YoY
+5.2%
EPS Growth YoY
-56.1%
Price Returns
2W
+15.5%
1M
-6.6%
3M
-12.4%
6M
-19.9%
12M
+6.8%
Technicals
52W High
$72.16
52W Low
$43.20
50d MA
$52.49
200d MA
$57.49
RSI (14)
66.80
ATR (14)
$1.92
Beta
1.49
Avg Volume
3.1M
Dividends
Div Rate
$0.32
Div Yield
0.6%
Frequency
4
Ex-Div Date
Feb 13, 2026
Analyst Price Targets
Consensus
$69.33
High
$79.00
Low
$62.00
Median
$69.00
Data updated apr 27, 2026 4:22am
· Source: financialmodelingprep.com